A phase I safety and pharmacokinetic study of SU011248 [sunitinib] in combination with docetaxel in patients with advanced solid tumors

Trial Profile

A phase I safety and pharmacokinetic study of SU011248 [sunitinib] in combination with docetaxel in patients with advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2008

At a glance

  • Drugs Docetaxel; Sunitinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Jul 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top